PREVENT is a multi-center, placebo-controlled study investigating the safety and durability of effect of subcutaneous avexitide (formerly exendin
9-39) in post-bariatric surgical patients who experience dangerously low, postprandial blood glucose levels known as post-bariatric hypoglycemia.
Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin
Glucagon-like peptide (GLP)-1 (9-36) amide-mediated cytoprotection is blocked by exendin
(9-39) yet does not require the known GLP-1 receptor.
The Gila's venom contains the compound Exendin which is being turned into a new drug to fight Type 2 diabetes.
Exendin is similar to a natural hormone called GLP1 and has the power to control the secretion of the body's own insulin.
Exendin was isolated from the 18-inch Gila Monster's poisonous saliva by scientists studying the eating habits of animals.
Exendin is similar to a natural hormone called GLP1 and can control the secretion of the body's own insulin.
Glucose levels increased from 0 to 60 min in all groups after an IP injection of the GLP-1 (7-36) receptor antagonist exendin
Administration of an insulinotropic GLP-1 agonist, exendin
(ex-4), inhibits food intake, reducing body mass  while stimulating adult dentate gyrus neurogenesis .
Further evidence for an exendin
receptor on dispersed acini from guinea pig pancreas.
Abdelli et al., "JNK3 is required for the cytoprotective effect of exendin
4," Journal of Diabetes Research, vol.
Chan, "Gene therapy for diabetes: metabolic effects of helper-dependent adenoviral exendin
4 expression in a diet-induced obesity mouse model," Molecular Therapy, vol.